Now live: Pro — the full 13F research suite for serious investorsSee pricing →
Octagon Capital Advisors LP

Q2 2023 · 13F-HR

Octagon Capital Advisors LPholdings as filed

Filed 2023-08-14 · accession 0001214659-23-011268

$718.7M
Reported value
41
Positions
2023-06-30
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
03753U106APLSUSDAPELLIS PHARMACEUTICALS INC$238.5M33.2%2,618,300CommonSOLE
925050106VRNAVERONA PHARMA PLC$52.2M7.26%2,468,000CommonSOLE
23257D103CBAYUSDCYMABAY THERAPEUTICS INC$50.1M6.96%4,570,918CommonSOLE
03969F109RCUSARCUS BIOSCIENCES INC$40.0M5.56%1,968,000CommonSOLE
G76279101ROIVROIVANT SCIENCES LTD$39.4M5.48%3,904,000CommonSOLE
60468T105MRTXEURMIRATI THERAPEUTICS INC$27.1M3.77%750,000CommonSOLE
15117B202CLDXCELLDEX THERAPEUTICS INC NEW$25.8M3.59%759,898CommonSOLE
92790C104VRDNVIRIDIAN THERAPEUTICS INC$22.0M3.06%923,000CommonSOLE
10806X102BBIOBRIDGEBIO PHARMA INC$21.0M2.92%1,219,200CommonSOLE
282559103ETNBGBP89BIO INC$20.2M2.81%1,066,784CommonSOLE
254604101IRONDISC MEDICINE INC$18.4M2.56%415,000CommonSOLE
92764N102VIRVIR BIOTECHNOLOGY INC$15.9M2.22%650,100CommonSOLE
75974E103RENEO PHARMACEUTICALS INC$15.5M2.16%2,368,587CommonSOLE
875372203TNDMTANDEM DIABETES CARE INC$11.7M1.62%474,929CommonSOLE
008064107AEROVATE THERAPEUTICS INC$10.7M1.48%621,712CommonSOLE
46565G1045E7ITEOS THERAPEUTICS INC$7.9M1.10%596,000CommonSOLE
26818M108DYNDYNE THERAPEUTICS INC$7.8M1.08%692,945CommonSOLE
457669307INSMINSMED INC$7.7M1.08%367,000CommonSOLE
02083G100NVLSEURALPINE IMMUNE SCIENCES INC$7.7M1.07%750,000CommonSOLE
89422G107TVTXTRAVERE THERAPEUTICS INC$7.6M1.06%495,000CommonSOLE
374163103GERNGERON CORP$7.3M1.02%2,278,000CommonSOLE
98422T100XILIO THERAPEUTICS INC$6.4M0.88%2,425,000CommonSOLE
037326105ANTXAN2 THERAPEUTICS INC$6.1M0.85%720,900CommonSOLE
471871103JASPER THERAPEUTICS INC$6.1M0.85%4,468,114CommonSOLE
92686J106VKTXVIKING THERAPEUTICS INC$6.1M0.85%375,000CommonSOLE
03589W102ANNXANNEXON INC$5.8M0.81%1,660,000CommonSOLE
38000Q102GLYCEURGLYCOMIMETICS INC$5.2M0.73%3,000,000CommonSOLE
38341P102GOSSGOSSAMER BIO INC$4.7M0.66%3,958,069CommonSOLE
528872302LXRXLEXICON PHARMACEUTICALS INC$4.4M0.61%1,923,076CommonSOLE
86366E106GPCRSTRUCTURE THERAPEUTICS INC$3.1M0.43%75,000CommonSOLE
69353Y103PMVPPMV PHARMACEUTICALS INC$2.9M0.41%470,000CommonSOLE
152309100CNTACENTESSA PHARMACEUTICALS PLC$2.5M0.35%411,928CommonSOLE
68622P109ORICORIC PHARMACEUTICALS INC$2.1M0.30%277,000CommonSOLE
86150R107STOKSTOKE THERAPEUTICS INC$2.0M0.27%185,669CommonSOLE
46583P102IVERIC BIO INC$2.0M0.27%50,000PUTSOLE
426897302CTRVGBPHEPION PHARMACEUTICALS INC$1.6M0.23%155,000CommonSOLE
92337R101VERAVERA THERAPEUTICS INC$1.1M0.16%70,000CommonSOLE
720795103PIRSEURPIERIS PHARMACEUTICALS INC$1.1M0.15%6,600,000CommonSOLE
55910K108MAGENTA THERAPEUTICS INC$416,9000.06%550,000CommonSOLE
45790W108INOZYME PHARMA INC$276,8400.04%49,702CommonSOLE
61225M102GLUEMONTE ROSA THERAPEUTICS INC$136,3150.02%19,900CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.